Abstract:Background Compound mutations of TNNT2R141W/+ (encoding troponin T) and MYPNS1296T/+ (encoding myopalladin) are associated with familial left ventricle non-compaction cardiomyopathy (LVNC). However, it remains unclear in which would be the pathogenic mutation, the underlying mechanism, and the target therapy for LVNC. Methods Knock-in C57BL/6J mice harboring mutations in orthologous genes in Tnnt2R154W or/and MypnS1291T and human cardiomyocytes derived from iPSC of healthy donors and LVNC patients (LVNC-hCM) were employed for disease modeling, omics analysis, mechanistic study, and drug development. Results Using knock-in mice for disease modeling, it was clarified that the orthologous mutation in Tnnt2, but not in Mypn, led to cardiac hypertrabeculation, noncompaction, and heart failure. 3D protein structure modeling by Swiss-model found a loss of slat bridge between TNNT2(R141W) and E-257 in tropomyosin, contributing to the decreased cardiac contraction. Further mechanistic study discovered that troponin T (TNNT2) appears to function as an HDAC1 sponge in cardiomyocyte nuclei. The compromised association between nuclear TNNT2(R141W) and HDAC1 causes cardiac epigenetic perturbation and subsequentially leads to transcriptional dysregulation. The downregulation of cardiac muscular genes was concomitant with the impairment of cardiac contraction, which would be partially rescued by pan HDAC inhibitor. Besides, the upregulation of TGFβ-signaling molecules and EZH2 did contribute to cardiac growth defects, which were mitigated by TGFβR1 inhibitor (A83-01) and EZH2 inhibitor (GSK503), respectively. Simvastatin, a hit drug identified from the repurposed drug screening, can restore nuclear TNNT2(R141W)-HDAC1 association, thereby recovering cardiac epigenetic, translational profiles, growth and function in LVNC-hCM in vitro and cardiac function in LVNC mice harboring Tnnt2R154W in vivo. The cardiac function was significantly improved in the proband receiving 5 mg once daily for consecutive two years. Conclusion Mutant TNNT2(R141W) diminished its nuclear HDAC1 sponge function in cardiomyocyte to induce LVNC pathogenesis through perturbating cardiac epigenetic and the gene expressions. Targeting to HDAC, TGFβ, EZH2 may rescue part of cardiac pathological signaling. Simvastatin can act as a chemical chaperone to comprehensively recover cardiac epigenetic via restoring nuclear TNNT2(R141W)-HDAC1 association.

In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin

NEXN Inhibits GATA4 and Leads to Atrial Septal Defects in Mice and Humans

Identification and Functional Prediction of Long Non-Coding RNAs in Dilated Cardiomyopathy by Bioinformatics Analysis

Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

1-Deoxynojirimycin Promotes Cardiac Function and Rescues Mitochondrial Cristae in Mitochondrial Hypertrophic Cardiomyopathy.

LncRNA ZNF593-AS Alleviates Contractile Dysfunction in Dilated Cardiomyopathy

Cardiac Overexpression of XIN Prevents Dilated Cardiomyopathy Caused by TNNT2 ΔK210 Mutation

Cardiac Overexpression Of Xin Prevents Dilated Cardiomyopathy Caused By Tnnt2 Delta K210 Mutation

Targeting mutant TNNT2-induced epigenetic perturbation and pathogenic signaling in left ventricular non-compaction cardiomyopathy

Abstract P439: Harnessing Multiscale Models Of A Dilated Cardiomyopathy Mutation For Precision Medicine

Nexilin in cardiomyopathy: unveiling its diverse roles with special focus on endocardial fibroelastosis

Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice

SnRNA-seq reveals differential functional transcriptional pathway alterations in three mutant types of dilated cardiomyopathy

Ning Sun Dilated Cardiomyopathy Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial

Up-regulated lncRNA SNHG9 mediates the pathogenesis of dilated cardiomyopathy via miR-326/EPHB3 axis

Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin T

The Molecular Role of Immune Cells in Dilated Cardiomyopathy

LCZ696 Improves Cardiac Function Via Alleviating Drp1-mediated Mitochondrial Dysfunction in Mice with Doxorubicin-Induced Dilated Cardiomyopathy.

Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

Non-cell autonomous cardiomyocyte regulation complicates gene supplementation therapy for<i>LMNA</i>cardiomyopathy

Identification of BMP10 as a Novel Gene Contributing to Dilated Cardiomyopathy